Cargando…

Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials

BACKGROUND: Previous studies have demonstrated an association between prostate-specific antigen (PSA) kinetics and predictive value for treatment outcomes. Abiraterone acetate (AA) is a newly approved cytochrome-P450C17 inhibitor for treatment of metastatic castration-resistant prostate cancer (mCRP...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakayama, Masahiko, Kobayashi, Hisanori, Takahara, Tomihiro, Oyama, Ryo, Imanaka, Keiichiro, Yoshizawa, Kazutake
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898460/ https://www.ncbi.nlm.nih.gov/pubmed/27278777 http://dx.doi.org/10.1186/s12894-016-0148-4

Ejemplares similares

Androgen dynamics and serum PSA in patients treated with abiraterone acetate
por: Ryan, C J, et al.
Publicado: (2014)

Early Prediction of Therapy Response to Abiraterone Acetate Using PSA Subforms in Patients with Castration Resistant Prostate Cancer
por: Schlack, Katrin, et al.
Publicado: (2016)

Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer
por: Mikah, Phillip, et al.
Publicado: (2016)

PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate
por: España, Sofia, et al.
Publicado: (2020)

Patient Preferences and Urologist Judgments on Prostate Cancer Therapy in Japan
por: Nakayama, Masahiko, et al.
Publicado: (2018)

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL
por: Bryce, A H, et al.
Publicado: (2017)

A Phase 2 Study of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer Who Had Received Docetaxel-based Chemotherapy
por: Satoh, Takefumi, et al.
Publicado: (2014)

A Phase 2 Trial of Abiraterone Acetate in Japanese Men with Metastatic Castration-resistant Prostate Cancer and without Prior Chemotherapy (JPN-201 Study)
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study
por: Koroki, Yosuke, et al.
Publicado: (2021)

Temperature Control of psaA Expression by PsaE and PsaF in Yersinia pestis
por: Quinn, Joshua D., et al.
Publicado: (2019)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
por: Linden-Castro, Edgar, et al.
Publicado: (2014)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Real‑world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer
por: Tsujino, Takuya, et al.
Publicado: (2023)

Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Uchimoto, Taizo, et al.
Publicado: (2021)

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
por: Chi, Kim N., et al.
Publicado: (2023)

Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2014)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

Prognostic significance of a novel indicator (PSA(postd3)/PSA(pre)) for PSA recurrence in patients after radical prostatectomy
por: Zhou, Zhien, et al.
Publicado: (2019)

PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide: A retrospective case-report study
por: Bosso, Davide, et al.
Publicado: (2017)

Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort
por: Komura, Kazumasa, et al.
Publicado: (2019)

Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml
por: Chang, Tsung-Hsin, et al.
Publicado: (2020)

Lenalidomide decreased the PSA level for castration‐resistant prostate cancer: a case report
por: Shimokihara, Kota, et al.
Publicado: (2018)

Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials
por: Grayling, Michael J., et al.
Publicado: (2022)

Useful predictors of progression‐free survival for Japanese patients with LATITUDE‐high‐risk metastatic castration‐sensitive prostate cancer who received upfront abiraterone acetate
por: Takahara, Kiyoshi, et al.
Publicado: (2021)

Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
por: Facchini, Gaetano, et al.
Publicado: (2016)

Correlation Between Trough Level of Abiraterone and Prostate-Specific Antigen (PSA) Response in Metastatic Hormone-Sensitive Prostate Cancer
por: Myint, Zin W., et al.
Publicado: (2022)

Establishment of reference intervals for serum [−2]proPSA (p2PSA), %p2PSA and prostate health index in healthy men
por: Wu, Zhi-Yu, et al.
Publicado: (2019)

Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer
por: Han, Kyung Seok, et al.
Publicado: (2015)

Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
por: Strittmatter, F, et al.
Publicado: (2011)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Abiraterone Acetate
Publicado: (2012)

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer
por: Tsuchiya, Tomohiro, et al.
Publicado: (2019)

Abiraterone Acetate: Targeting Persistent Androgen Dependence in Castration-Resistant Prostate Cancer
por: Harshman, Lauren C., et al.
Publicado: (2013)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
por: Yamamoto, Yutaka, et al.
Publicado: (2018)

PSA screening – for whom and when?
por: Albers, Peter
Publicado: (2019)

Antigenic determinants of prostate-specific antigen (PSA) and development of assays specific for different forms of PSA.
por: Nilsson, O., et al.
Publicado: (1997)

Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer
por: Tomioka, Atsushi, et al.
Publicado: (2014)

Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer
por: Burchardt, Wojciech, et al.
Publicado: (2018)

Assessment of the many faces of PsA: single and composite measures in PsA clinical trials
por: McGagh, Dylan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6v47gcho6s1gtd6ovn6tibkn9t